Cannabis Report
Home > Boards > US Listed > Biotechs >

BioTime, Inc. (BTX)

BTX RSS Feed
Add BTX Price Alert      Hide Sticky   Hide Intro
Moderator: ahab333
Search This Board: 
Last Post: 5/26/2018 11:29:02 AM - Followers: 69 - Board type: Free - Posts Today: 0

 

BioTime, Inc.  (BTX)

 

 
 

 

http://www.biotimeinc.com/

 

 

 

Company Information:

BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502

Phone: 510-521-3390
      Fax: 510-521-3389

 

CIK

0000876343

 

 

BioTime, Inc. (NYSE AMEX: BTX) is a biotechnology company engaged in two areas of biomedical research and product development:

  • Stem cell technology and products for use in regenerative medicine.  These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.
  • Blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.  Our lead product is Hextend® which is being marketed by Hospira, Inc. and CJ CheilJedang Corp. under exclusive licenses from us

 

The Potential of Regenerative Medicine

Regenerative medicine refers to therapies based on human embryonic stem ("hES") cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The great scientific and public interest in regenerative medicine lies in the potential of hES cells to transform into any cell type of the human body. hES cells therefore show considerable potential as a source of new therapies for a host of currently-incurable diseases such as: diabetes, stroke, Alzheimer's and Parkinson's disease, heart failure, arthritis, muscular dystrophy, spinal cord injury, macular degeneration, hearing loss, kidney and liver failure, as well as many other disorders that may be treated by replacing diseased or damaged organ tissues. In response to the unusual potential of the field, the State of California has allocated $3 billion over the next 10 years to fund basic research, and President Obama has lifted previous restrictions for federal funding of stem cell research.

Led by Dr. Michael West, considered by many to be a founding father of the stem cell industry, BioTime has assembled an array of products and associated intellectual property that give it the potential to be a leader in this exciting new field of medicine.

We are implementing a near-term revenues strategy in the regenerative medicine field by seeking to develop and market advanced hES products and technology that can be used by researchers at universities and biopharmaceutical companies. These research-only products generally can be marketed without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to human therapeutic products. We may also initiate development programs for human therapeutic applications if sufficient capital becomes available to us or through joint efforts with industry partners.

BioTime is leveraging its product development strategy on two key technology platforms:
 

  • • An advanced iPS technology allowing the transformation of human cells of the body back to a primordial stem cell state equivalent to embryonic stem cells. Using this technology with patient specific stem cells, rather than stem cells derived from embryos donated by unrelated people, may reduce the incidence of rejection of tissue grafts.
     
  • ACTCellerate™ technology that permits the generation of scalable and highly purified cells of the human body.

See this link for more information:  http://www.biotimeinc.com/aboutBT.htm

 

 

 

 

 

 

Management: 

http://www.biotimeinc.com/management.htm
 

 

Dr. Michael West, CEO

Dr. West is the Chief Executive Officer of BioTime, Inc. (NYSE AMEX: BTIM) and Embryome Sciences, Inc. of Alameda, California. The Companies are focused on developing an array of research and therapeutic products using human embryonic stem cell technology. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He has focused his academic and business career on the application of developmental biology to the age-related degenerative disease. He was the Founder of Geron Corporation of Menlo Park, California (Nasdaq: GERN) and from 1990 to 1998 he was a Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research collaboration between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. From 1998 to 2007 he was President and Chief Scientific Officer at Advanced Cell Technology, Inc. (OTCBB: ACTC) where he managed programs in animal cloning, human somatic cell nuclear transfer, retinal differentiation, and ACTCellerate, a technology for the multiplex derivation and characterization of clonal human embryonic progenitor cell lines. 

Dr. West's complete CV and background on his research interests are available online at: http://www.michaelwest.org/


 

 

 

 

Recent News: 

http://www.b2i.us/profiles/investor/ResLibrary2.asp?BzID=1152&GoTopage=&Category=1802&t=
 

 

http://finance.yahoo.com/q/h?s=BTX+Headlines

 

Subsidiaries
http://www.biotimeinc.com/subsidiaries/


 

 

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000876343&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

 

 

Transfer Agent:

American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038

 

Investor Relations:

Judith Segall

VP of Administration, Corporate Secretary

isegall@biotimemail.com

Phone:  510.521.3390 ext 301

 

 

 


 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock.   Being a moderator isn't a sign of endorsement.

  

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp

 

Cannabis Report
BTX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BTX News: BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites 05/24/2018 07:00:00 AM
BTX News: AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Cong... 05/17/2018 07:00:00 AM
BTX News: Current Report Filing (8-k) 05/10/2018 04:32:59 PM
BTX News: Quarterly Report (10-q) 05/10/2018 04:26:07 PM
BTX News: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 05/10/2018 04:05:00 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#941   Aubrey de Grey is VP of New Technology DeepDive 05/26/18 11:29:01 AM
#940   BioTime Further Expands OpRegen(R) Clinical Trial in Dry-AMD terry hallinan 05/24/18 09:39:27 AM
#939   OCATA trials were said to restart early 18. DeepDive 05/23/18 01:46:19 PM
#938   Regarding this Clinical Trial: That’s a wet AMD. Think DeepDive 05/23/18 01:37:44 PM
#937   Yes Cinci, there are so many variables or ahab333 05/23/18 11:49:52 AM
#936   It has been fun to speculate about future Cincinnatus 05/22/18 11:08:50 AM
#935   Cox's January Comments on Renelon bobby2loaves 05/22/18 07:31:31 AM
#934   A reference for C's claims is within this link: DeepDive 05/22/18 06:00:04 AM
#933   I hear you, C., with respect to Cox's DeepDive 05/22/18 05:51:15 AM
#932   hair rejuvenation!!!!!! terry hallinan 05/21/18 08:20:21 PM
#931   Of course this is all speculation. You Cincinnatus 05/21/18 04:27:38 PM
#930   Distribution Date bobby2loaves 05/21/18 11:39:07 AM
#929   when is distribution date jwp25 05/21/18 08:47:23 AM
#928   One reason to hype it now is to DeepDive 05/21/18 12:13:36 AM
#927   We agree that Cox is all science, and Cincinnatus 05/20/18 11:33:38 PM
#926   Thanks, DeepDive. terry hallinan 05/20/18 10:27:18 PM
#925   Terry, There will always be irresponsible doctors willing DeepDive 05/20/18 12:21:14 PM
#924   Cin. I’m familiar with Cox. His writing is interesting DeepDive 05/20/18 12:06:58 PM
#923   I agree with Cincinnatus bobby2loaves 05/20/18 10:14:02 AM
#922   I'm not sure you understand the significance of Cincinnatus 05/20/18 10:04:37 AM
#921   CE mark is a must before any therapist terry hallinan 05/20/18 07:16:13 AM
#920   Even if scarless healing is possible at all, DeepDive 05/20/18 12:52:08 AM
#919   CE mark is a must before any therapist DeepDive 05/20/18 12:45:43 AM
#918   I'm wondering if anyone else is considering another Cincinnatus 05/20/18 12:29:30 AM
#917   There are historical precedents of new products entering pymadams 05/19/18 02:46:56 PM
#916   DeepDive, The near term value generating news will have terry hallinan 05/19/18 02:05:36 PM
#915   The near term value generating news will have DeepDive 05/19/18 12:38:41 AM
#914   Sunday News? bobby2loaves 05/18/18 01:51:21 PM
#913   Nice rise in shares today, Friday albeit on ahab333 05/18/18 12:47:41 PM
#912   I guess maybe now that they think terry hallinan 05/17/18 10:50:21 AM
#911   Wonder if 5/18 Keynote Address Will Give Us bobby2loaves 05/17/18 08:25:12 AM
#910   From teleconference: terry hallinan 05/14/18 10:59:27 PM
#909   DeepDive, I don't really have any argument against you terry hallinan 05/12/18 02:14:23 PM
#908   Old Ocata nee advanced cell tech (Dr West) International DeepDive 05/12/18 01:46:49 PM
#907   DeepDive, Ahab; terry hallinan 05/12/18 03:48:07 AM
#906   While I have deep respect for Dr West, DeepDive 05/12/18 01:04:43 AM
#905   Link to call transcript BioTime's (BTX) CEO Adi DeepDive 05/12/18 12:54:26 AM
#904   Biotime (btx) 1st quarter results: UGH but long ahab333 05/11/18 12:53:34 PM
#903   That's a good question Terry, and I really ahab333 05/09/18 04:00:08 PM
#902   Ahab. Is GTHP better at detecting cancer than dogs' terry hallinan 05/09/18 11:50:23 AM
#901   Terry, I am familiar with photonics. I ahab333 05/09/18 11:06:08 AM
#899   Ahab, I will be here until it is terry hallinan 05/08/18 04:22:58 PM
#898   Hey Terry, no caution necessary. I'm here ahab333 05/08/18 03:56:48 PM
#897   "The Market Can Remain Irrational Longer Than You terry hallinan 05/08/18 03:39:25 PM
#896   Bobby, funny you should be thinking of a ahab333 05/08/18 01:49:38 PM
#895   BTX Treading Near 9-Year Lows bobby2loaves 05/08/18 11:29:21 AM
#894   To be clear, the objections are to rapid terry hallinan 05/03/18 10:48:15 AM
#893   In one case recently, the CEO, massive owner DeepDive 05/03/18 12:04:07 AM
#892   To be clear, the objections are to rapid DeepDive 05/02/18 11:58:31 PM
#891   Most micro cap biotech just dilute owners to death.[/co terry hallinan 05/02/18 05:16:02 PM
PostSubject